Aptose Biosciences Inc. (NASDAQ:APTO), concluded the day at $6.32 after seeing a rise of 1.52% that brought its market cap to $470.8 million. Volatility for the week was 6.82%, which was 2.65% in the previous month. The company closed the session with a trading volume of 597543 shares, below from its average daily trading volume of 1.01 million. Net income posted by the company in last 12 months was -$26.30 million.
Aptose Biosciences Inc. (Nasdaq: APTO), hosted a key opinion leader (KOL) event on Wednesday, February 5th, 2020 in New York City. In addition, William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, Gregory K. Chow, Executive Vice President and Chief Financial Officer and Jotin Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, presented at the BIO CEO & Investor Conference on Monday, later on February 10th, 2020 in New York City.
Additionally, Rafael Bejar M.D., Ph.D., Aptose’s Chief Medical Officer, served as moderator and provided an overview of the rationale and strategy for the development of CG-806 in myeloid malignancies. CG-806 is currently in an ongoing Phase 1a/b clinical trial for the treatment of patients with relapsed / refractory B-cell malignancies, including CLL and NHL, and in 1H / 2020 is planned to enter a separate clinical trial in patients with relapsed / refractory AML and high-risk MDS.
When looking at performance, we see the stock demonstrating a weekly performance of 4.88% while keeping a monthly performance of -12.01%. Quarterly performance saw a rise of 17.11% but succeeded to record a yearly performance of 227.89% while showing YTD performance of 9.88% which was 203.9% for last six months. The 52-week range for the stock was 1.81 – 9.25 that put its current price at a premium of 249.45% to the 52-week low price whereas it is trading at a discount of -31.64% to the 52-week high price.
The Biotechnology company’s EPS for trailing 12 months is $-0.53 and it is estimated to be posting an EPS of $-0.11 for the current quarter. The Beta number showed the stock is subject to risk 77% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is -55.1% while ROE for the same period is -61.6%.
The outstanding share count is 75.57 million shares but the size of available float is 69.98 million shares. The stock’s current price is trailing SMA-200 by 57.39% which is also -7.64% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 12.77% to the SMA-20.